摘要
目的研究水飞蓟宾+恩替卡韦治疗乙型病毒性肝炎合并肝硬化(HB+C)的临床疗效。方法158例HB+C患者,依据随机数字表法分为A组和B组,每组79例。B组实施恩替卡韦分散片治疗,A组在B组基础上加用水飞蓟宾治疗。比较两组患者临床治疗效果、治疗后肝功能指标[谷丙转氨酶(ALT)、血清白蛋白(ALB)、总胆红素(TBIL)]和肝纤维化指标[透明质酸(HA)、Ⅲ型前胶原(PCⅢ)、Ⅳ型胶原(Ⅳ-C)、层粘连蛋白(LN)]、不良反应发生情况。结果A组患者的临床治疗总有效率为98.73%,高于B组的87.34%,差异有统计学意义(P<0.05)。A组患者的ALT、ALB、TBIL、HA、PCⅢ、Ⅳ-C、LN分别为(54.12±10.22)U/L、(38.19±5.42)g/L、(26.12±4.98)μmol/L、(106.22±36.24)μg/L、(97.52±31.24)μg/L、(67.12±30.65)μg/L、(100.02±24.02)μg/L,B组分别为(73.64±11.64)U/L、(33.15±4.69)g/L、(30.57±5.22)μmol/L、(146.23±54.27)μg/L、(124.47±45.31)μg/L、(77.52±34.58)μg/L、(178.67±29.04)μg/L;A组患者的ALT、TBIL、HA、PCⅢ、Ⅳ-C、LN水平均低于B组,ALB水平高于B组,差异均有统计学意义(P<0.05)。A组患者的不良反应发生率为3.80%,显著低于B组的12.66%,差异有统计学意义(P<0.05)。结论水飞蓟宾+恩替卡韦治疗HB+C的临床疗效确切,可有效改善肝功能水平和肝纤维指标,减少不良反应发生。
Objective To study the clinical efficacy of silibinin combined with entecavir in the treatment of hepatitis B complicated with cirrhosis(HB+C).Methods A total of 158 cases of HB+C patients were divided into group A and group B according to the random numerical table,with 79 cases in each group.Group B was treated with entecavir dispersible tablets,and group A was treated with silibinin on the basis of group B.Both groups were compared in terms of clinical effect,liver function indexes[alanine aminotransferase(ALT),serum albumin(ALB),total bilirubin(TBIL)],liver fibrosis indexes[hyaluronic acid(HA),procollagen Ⅲ(PCⅢ),type Ⅳ collagen(Ⅳ-C),laminin(LN)],and the occurrence of adverse reactions.Results The total effective rate of clinical treatment in group A was 98.73%,which was higher than 87.34% in group B,and the difference was statistically significant(P<0.05).The ALT,ALB,TBIL,HA,PCⅢ,Ⅳ-C and LN of group A were(54.12±10.22)U/L,(38.19±5.42)g/L,(26.12±4.98)μmol/L,(106.22±36.24)μg/L,(97.52±31.24)μg/L,(67.12±30.65)μg/L and(100.02±24.02)μg/L,and those of group B were(73.64±11.64)U/L,(33.15±4.69)g/L,(30.57±5.22)μmol/L,(146.23±54.27)μg/L,(124.47±45.31)μg/L,(77.52±34.58)μg/L and(178.67±29.04)μg/L.The levels of ALT,TBIL,HA,PCⅢ,Ⅳ-C,and LN in group A were lower than those in group B,and the level of ALB was higher than that in group B.All the differences were statistically significant(P<0.05).The incidence of adverse reactions in group A was 3.80%,which was significantly lower than 12.66% in group B,and the difference was statistically significant(P<0.05).Conclusion Silibinin combined with entecavir has definite clinical efficacy in the treatmnet of HB+C,and can effectively improve the level of liver function and liver fiber index,and reduce the occurrence of adverse reactions.
作者
孙莺莺
SUN Ying-ying(Department of Infection,Lingyuan Central Hospital,Lingyuan 122500,China)
出处
《中国现代药物应用》
2022年第17期119-121,共3页
Chinese Journal of Modern Drug Application
